These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 16860461)

  • 41. Leuprolide in the treatment of endometrial cancer.
    Markman M; Kennedy A; Webster K; Peterson G; Kulp B; Belinson J
    Gynecol Oncol; 1997 Sep; 66(3):542. PubMed ID: 9299275
    [No Abstract]   [Full Text] [Related]  

  • 42. Intracranial metastatic prostate carcinoma presenting as intermittent double vision.
    Saito Y; Kondo Y; Shimizu H; Kunimoto K; Nishimura T
    Urology; 2004 Sep; 64(3):589-90. PubMed ID: 15351603
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Glucocorticoids and prostate cancer in castrate men.
    Plowman PN
    J Clin Oncol; 1999 Dec; 17(12):3856-60. PubMed ID: 10577863
    [No Abstract]   [Full Text] [Related]  

  • 44. Combined hypofractionated radiation and hormone therapy for the treatment of intermediate-risk prostate cancer.
    Yassa M; Fortin B; Fortin MA; Lambert C; Van Nguyen T; Bahary JP
    Int J Radiat Oncol Biol Phys; 2008 May; 71(1):58-63. PubMed ID: 18406883
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Medical therapy of locally advanced prostatic neoplasms].
    Boccardo F; Pace M; Perrotta A; Rubagotti A
    Minerva Urol Nefrol; 1995 Dec; 47(4):203-8. PubMed ID: 8711593
    [No Abstract]   [Full Text] [Related]  

  • 46. Radiation dose predicts for biochemical control in intermediate-risk prostate cancer patients treated with low-dose-rate brachytherapy.
    Ho AY; Burri RJ; Cesaretti JA; Stone NN; Stock RG
    Int J Radiat Oncol Biol Phys; 2009 Sep; 75(1):16-22. PubMed ID: 19289266
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Re: "Current role of chemotherapy in the treatment of hormone-resistant metastatic prostate cancer" by Xavier Breton, Eric Lechevallier, Christian Coulange, Prog. Urol., 2005, 15, 398-404].
    Berdah JF
    Prog Urol; 2005 Dec; 15(6):1160. PubMed ID: 16429675
    [No Abstract]   [Full Text] [Related]  

  • 48. Re: Additional treatment for pT3 prostate cancer: now, later or never.
    Pitts WR
    BJU Int; 2008 Jul; 102(1):133; author reply 133-4. PubMed ID: 18564235
    [No Abstract]   [Full Text] [Related]  

  • 49. Leuprolide monotherapy for choroidal metastasis from prostate adenocarcinoma.
    Ameri H; Araujo JC; Gombos DS
    Arch Ophthalmol; 2012 Sep; 130(9):1225-6. PubMed ID: 22965610
    [No Abstract]   [Full Text] [Related]  

  • 50. Studies on extragonadal androgen: hormonal changes of the prostatic cancer patients on antiandrogenic therapy after orchiectomy.
    Fukuda Y
    Kobe J Med Sci; 1968 Mar; 14(1):1-23. PubMed ID: 5674440
    [No Abstract]   [Full Text] [Related]  

  • 51. Efficacy of primary hormone therapy for localized or locally advanced prostate cancer: results of a 10-year follow-up.
    Akaza H; Homma Y; Usami M; Hirao Y; Tsushima T; Okada K; Yokoyama M; Ohashi Y; Aso Y;
    BJU Int; 2006 Sep; 98(3):573-9. PubMed ID: 16925756
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Depression during hormonal treatment of prostate cancer.
    Rosenblatt DE; Mellow A
    J Am Board Fam Pract; 1995; 8(4):317-20. PubMed ID: 7572297
    [No Abstract]   [Full Text] [Related]  

  • 53. [Castration in the treatment of locally advanced or metastatic prostate cancer].
    Mongiat-Artus P
    Rev Prat; 2013 Apr; 63(4):509-10. PubMed ID: 23682480
    [No Abstract]   [Full Text] [Related]  

  • 54. Managing hot flashes in men being treated for prostate cancer.
    Baum NH; Torti DC
    Geriatrics; 2007 Nov; 62(11):18-21. PubMed ID: 17999566
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Global update on defining and treating high-risk localized prostate cancer with leuprorelin: a European perspective.
    Boccon-Gibod L
    BJU Int; 2007 Jan; 99 Suppl 1():2-5; discussion 17-8. PubMed ID: 17229159
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Hormonal treatment of disseminated cancer of the prostate: results and survival obtained in a series of 60 patients].
    Izquierdo Font AJ; Barnadas Molins A; Germa Lluch JR; Marcuello Gaspar E; López López JJ
    Actas Urol Esp; 1985; 9(3):231-6. PubMed ID: 4036688
    [No Abstract]   [Full Text] [Related]  

  • 57. Cost comparison of orchiectomy and leuprolide in metastatic prostate cancer.
    Bonzani RA; Stricker HJ; Peabody JO; Menon M
    J Urol; 1998 Dec; 160(6 Pt 2):2446-9. PubMed ID: 9817400
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Raloxifene can benefit prostate cancer.
    Health News; 2006 Aug; 12(8):2. PubMed ID: 16917966
    [No Abstract]   [Full Text] [Related]  

  • 59. Characterization of the intra-prostatic immune cell infiltration in androgen-deprived prostate cancer patients.
    Gannon PO; Poisson AO; Delvoye N; Lapointe R; Mes-Masson AM; Saad F
    J Immunol Methods; 2009 Aug; 348(1-2):9-17. PubMed ID: 19552894
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Rebuttal from authors re: Joaquim Bellmunt. Chemotherapy for prostate cancer in senior adults: are we treating the elderly or the frail? Eur Urol 2009;55:1310-2.
    Italiano A; Fizazi K
    Eur Urol; 2009 Jun; 55(6):1313-4. PubMed ID: 18849106
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.